Amylyx Pharmaceuticals (AMLX) News Today $3.60 +0.10 (+2.86%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Moderate Buy" from BrokeragesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has received an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, three have assigned aJanuary 15 at 2:48 AM | marketbeat.comAmylyx Pharmaceuticals Enters Underwriting Agreement for Public OfferingJanuary 13, 2025 | americanbankingnews.comAmylyx announces common stock offering, no amount givenJanuary 10, 2025 | markets.businessinsider.comAmylyx stock dips after pricing $60M stock offeringJanuary 10, 2025 | seekingalpha.comAmylyx Pharmaceuticals Prices Offering Of Approx. 17.1 Mln Shares At $3.50 Per ShareJanuary 10, 2025 | markets.businessinsider.comAmylyx Pharmaceuticals Announces Pricing of Public Offering of Common StockJanuary 10, 2025 | businesswire.comAmylyx Pharma Commences Underwritten Public Offering Of SharesJanuary 10, 2025 | markets.businessinsider.comAmylyx Pharmaceuticals Announces Proposed Public Offering of Common StockJanuary 9, 2025 | businesswire.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Justin B. Klee Sells 7,471 SharesJanuary 9, 2025 | insidertrades.comJustin B. Klee Sells 7,471 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) StockAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) CEO Justin B. Klee sold 7,471 shares of Amylyx Pharmaceuticals stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $4.04, for a total transaction of $30,182.84. Following the transaction, the chief executive officer now owns 3,176,788 shares of the company's stock, valued at $12,834,223.52. This represents a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.January 8, 2025 | marketbeat.comAmylyx appoints Dan Monahan as Chief Commercial OfficerJanuary 6, 2025 | markets.businessinsider.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Up 8.3% in DecemberAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 1,570,000 shares, an increase of 8.3% from the November 30th total of 1,450,000 shares. Based on an average daily trading volume, of 1,310,000 shares, the short-interest ratio is currently 1.2 days. Approximately 3.6% of the company's shares are sold short.December 31, 2024 | marketbeat.comGubra A/S: Gubra Announces New Collaboration with Amylyx Pharmaceuticals to Develop a Novel Long-acting GLP-1 Receptor AntagonistDecember 30, 2024 | finanznachrichten.deGubra and Amylyx team on novel long-acting GLP-1 receptor antagonist developmentDecember 30, 2024 | markets.businessinsider.comWhy Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now?December 30, 2024 | msn.comJane Street Group LLC Has $1.12 Million Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Jane Street Group LLC decreased its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 29.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 344,173 shares of the companDecember 30, 2024 | marketbeat.comXTX Topco Ltd Trims Stock Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)XTX Topco Ltd cut its position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 77.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,672 shares of the company's stock after sellingDecember 21, 2024 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine brokerages that are covering the stock, MarketBeat reports. Five analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one haDecember 21, 2024 | marketbeat.comFmr LLC Increases Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Fmr LLC grew its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 292.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 221,001 shares of the company's stock after acquiring an additional 164,622 shares during the quaDecember 18, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Reduces Stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Charles Schwab Investment Management Inc. lessened its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 42.1% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 302,270 shares of the company's stock after sDecember 18, 2024 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Sees Significant Decrease in Short InterestAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) saw a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 1,450,000 shares, a drop of 5.2% from the November 15th total of 1,530,000 shares. Based on an average daily trading volume, of 1,440,000 shares, the days-to-cover ratio is presently 1.0 days. Approximately 3.4% of the company's shares are sold short.December 17, 2024 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. trimmed its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 18.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 478,440 shares of the company's stock afteDecember 9, 2024 | marketbeat.comAmylyx announces design of LUCIDITY clinical trialDecember 5, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Keros Therapeutics (KROS), Century Therapeutics (IPSC)December 5, 2024 | markets.businessinsider.comWalleye Capital LLC Purchases 608,874 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Walleye Capital LLC grew its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 986.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 670,594 shares of the comDecember 4, 2024 | marketbeat.comAlpha Wave Global LP Invests $2.17 Million in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Alpha Wave Global LP acquired a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 669,487 shares of the company's stock, valued at approxiNovember 27, 2024 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Rating of "Moderate Buy" by BrokeragesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has received an average recommendation of "Moderate Buy" from the ten research firms that are presently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation, four have issued a buy recoNovember 26, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Raises Stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Connor Clark & Lunn Investment Management Ltd. increased its position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 41.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor ownedNovember 25, 2024 | marketbeat.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating Upgraded by Baird R WBaird R W raised shares of Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Monday.November 19, 2024 | marketbeat.comBaird Upgrades Amylyx Pharmaceuticals (AMLX)November 19, 2024 | msn.comTwist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On MondayNovember 18, 2024 | benzinga.comAmylyx upgraded to Outperform from Neutral at BairdNovember 18, 2024 | markets.businessinsider.comStrong Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising Avexitide Prospects and Stable Financial StandingNovember 18, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals upgraded to Outperform at Baird, shares riseNovember 18, 2024 | msn.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded by Robert W. Baird to Outperform RatingRobert W. Baird upgraded shares of Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and upped their price target for the company from $3.00 to $11.00 in a research note on Monday.November 18, 2024 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest UpdateAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 1,290,000 shares, a growth of 27.7% from the October 15th total of 1,010,000 shares. Based on an average daily trading volume, of 1,340,000 shares, the short-interest ratio is currently 1.0 days. Approximately 3.1% of the shares of the company are sold short.November 15, 2024 | marketbeat.comCautious Hold on Amylyx Pharmaceuticals Amid Uncertainty in Pipeline ProgressNovember 11, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comAmylyx Pharmaceuticals Q3 2024 Financial HighlightsNovember 9, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...November 8, 2024 | finance.yahoo.comHC Wainwright Issues Positive Forecast for Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock PriceHC Wainwright raised their price objective on Amylyx Pharmaceuticals from $8.00 to $12.00 and gave the company a "buy" rating in a research note on Friday.November 8, 2024 | marketbeat.comAmylyx Pharmaceuticals (AMLX) to Release Earnings on ThursdayAmylyx Pharmaceuticals (NASDAQ:AMLX) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 5, 2024 | marketbeat.comVentyx Biosciences: Ready To Escape "The Crash Cycle"November 5, 2024 | seekingalpha.comabrdn plc Has $6.39 Million Stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)abrdn plc boosted its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 1,567.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,972,242 shares of the company's stock aftNovember 3, 2024 | marketbeat.comBank of America Securities Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)October 29, 2024 | markets.businessinsider.comPerceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals IncOctober 25, 2024 | finance.yahoo.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at Bank of AmericaBank of America upgraded shares of Amylyx Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $4.20 to $10.00 in a research report on Wednesday.October 23, 2024 | marketbeat.comNeutral Stance on Amylyx Pharmaceuticals Amid Promising Data and UncertaintiesOctober 23, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $8.00 price objective on shares of Amylyx Pharmaceuticals in a research report on Friday.October 18, 2024 | marketbeat.comWhy Amylyx Pharmaceuticals Stock Was So Healthy This WeekOctober 18, 2024 | fool.com Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address AMLX Media Mentions By Week AMLX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMLX News Sentiment▼0.500.72▲Average Medical News Sentiment AMLX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMLX Articles This Week▼36▲AMLX Articles Average Week Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AbCellera Biologics News Today ArriVent BioPharma News Today Relay Therapeutics News Today Phibro Animal Health News Today Cogent Biosciences News Today Avid Bioservices News Today Sana Biotechnology News Today Avadel Pharmaceuticals News Today Septerna News Today Tyra Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMLX) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMLX Stock Alerts